Nuvation Bio Inc. Derivative Liability, Fair Value, Gross Liability
Nuvation Bio Inc. (NUVB) had Derivative Liability, Fair Value, Gross Liability of $2.87 million as of 2025-12-31, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2026-08-06
- 2025-12-31: Derivative Liability, Fair Value, Gross Liability $2.87M.
- 2025-09-30: Derivative Liability, Fair Value, Gross Liability $1.74M.
- 2025-03-31: Derivative Liability, Fair Value, Gross Liability $2.35M; Derivative Liability, Fair Value, Gross Liability as first filed $2.80M.
- 2024-12-31: Derivative Liability, Fair Value, Gross Liability $2.05M.
| Period end | Derivative Liability, Fair Value, Gross Liability | Derivative Liability, Fair Value, Gross Liability as first filed |
|---|---|---|
| 2025-12-31 | $2.87M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-03 | |
| 2025-03-31 | $2.35M 10-Q · filed 2025-08-07 | $2.80M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.05M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $908.00K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $1.44M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $1.81M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $353.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $590.00K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $972.00K 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $708.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $353.00K 10-Q · filed 2024-05-14 | $850.00K 10-K · filed 2023-03-15 |
| 2022-09-30 | $1.17M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $1.63M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $4.71M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $11.04M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $14.94M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $15.06M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $15.56M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |